Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 3/20 | 0.41 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292198 | 0.85 | LMNA (0.45) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL16099482 | 0.84 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL15893327 | 0.84 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL1583331 | 0.84 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL18039264 | 0.83 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL6025793 | 0.83 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL6025787 | 0.83 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL10674095 | 0.83 | DUT (0.42) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL4745548 | 0.82 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL12482651 | 0.82 | TK1 (0.45) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-5741900-A | REACTING PROTECTED FLUOROURIDINE WITH SUCCINIC ANHYDRIDE, ATTACHING TO LONG-CHAIN ALKYLAMINE CONTROLLED PORE GLASS IN ANHYDROUS PYRIDINE IN PRESENCE OF DIMETHYLAMINOPYRIDINE AND DIMETHYLAMINOPROPYL/ETHYLCARBODIIMIDE | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1998-04-21 | — | — | US | disclosed |
| US-5663321-A | INHIBITOR OF THYMIDYLATE SYNTHASE; ANTICANCER/ANTITUMOR AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-09-02 | — | — | US | disclosed |
| US-5614505-A | 5-FLUOROURIDINE OR 5-FLUORODEOXYURIDINE, DRUG DELIVERY, IMPROVED BIOAVAILABILITY, ANTICARCINOGENIC AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-03-25 | — | — | US | disclosed |
| US-5457187-A | Antitumor, anticarcinogeic agents | BOARD OF REGENTS UNIVERSITY OF NEBRASKA (US) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885ALOX12 4305/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885ALOX12 3882/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885ALOX12 3882/4885 |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | LMNA 3368/4885SMN1; SMN2 1537/4885ALOX12 2326/4885 |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | LMNA 3368/4885SMN1; SMN2 1537/4885ALOX12 2326/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885ALOX12 3882/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | LMNA 926/4885SMN1; SMN2 1542/4885ALOX12 4142/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885ALOX12 4305/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | LMNA 3368/4885SMN1; SMN2 1537/4885ALOX12 2326/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | LMNA 1139/4885SMN1; SMN2 668/4885ALOX12 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.